Publications by authors named "V Moons"
From early 2020, a high demand for SARS-CoV-2 tests was driven by several testing indications, including asymptomatic cases, resulting in the massive roll-out of PCR assays to combat the pandemic. Considering the dynamic of viral shedding during the course of infection, the demand to report cycle threshold (Ct) values rapidly emerged. As Ct values can be affected by a number of factors, we considered that harmonization of semi-quantitative PCR results across laboratories would avoid potential divergent interpretations, particularly in the absence of clinical or serological information.
View Article and Find Full Text PDFArticle Synopsis
- Bevacizumab, a drug that inhibits VEGF-A, combined with chemotherapy has shown improved survival rates for patients with metastatic colorectal cancer (mCRC), but researchers are exploring another dual-blocker, vanucizumab, which targets both VEGF-A and angiopoietin-2 (Ang-2).
- In a phase II trial, 189 patients received either vanucizumab plus modified FOLFOX-6 chemotherapy or bevacizumab plus the same chemotherapy, with progression-free survival (PFS) as the main outcome measure.
- Results indicated that both treatments had similar PFS outcomes and safety profiles, with favorable response rates, but vanucizumab did not show significant advantages over bevacizumab
: Empirical treatment of ri (HP) depends on the local prevalence of clarithromycin resistance but data are lacking and culturing of HP is time-consuming. We evaluated RIDA®GENE assay (r-biopharm), a quantitative PCR assay for detecting HP and clarithromycin resistance mutations in gastric biopsies.: Gastric biopsies were obtained from each of 436 consecutive patients referred for gastroscopic investigation and results of qPCR were compared to culture and immunohistochemical staining (IHCS).
View Article and Find Full Text PDF